Successful treatment of secondary graft failure following unrelated cord blood transplant with hematopoietic growth factors in a pediatric patient with Fanconi anemia

2015 ◽  
Vol 19 (7) ◽  
pp. E181-E184 ◽  
Author(s):  
David Buchbinder ◽  
Loan Hsieh ◽  
Arash Mahajerin ◽  
Geetha Puthenveetil ◽  
Amit Soni ◽  
...  
Keyword(s):  
Growth Factors ◽  
Cord Blood ◽  
Pediatric Patient ◽  
Fanconi Anemia ◽  
Successful Treatment ◽  
Graft Failure ◽  
Hematopoietic Growth Factors ◽  
Cord Blood Transplant ◽  
Unrelated Cord Blood

scholarly journals Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival

2007 ◽  
Vol 13 (9) ◽  
pp. 1073-1082 ◽  
Author(s):  
Eliane Gluckman ◽  
Vanderson Rocha ◽  
Irina Ionescu ◽  
Marc Bierings ◽  
Richard E. Harris ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Risk Factor ◽  
Cord Blood ◽  
Fanconi Anemia ◽  
Risk Factor Analysis ◽  
Cord Blood Transplant ◽  
Unrelated Cord Blood

scholarly journals Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H

2008 ◽  
Vol 50 (4) ◽  
pp. 917-919 ◽  
Author(s):  
Mwe Mwe Chao ◽  
John E. Levine ◽  
James L. Ferrara ◽  
Laura Cooling ◽  
Kenneth R. Cooke ◽  
...  
Keyword(s):  
Cord Blood ◽  
Successful Treatment ◽  
Immune Hemolysis ◽  
Cord Blood Transplant ◽  
Unrelated Cord Blood

Results of Unrelated Cord Blood Transplants in Fanconi Anemia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2145-2145
Author(s):  
Eliane Gluckman ◽  
Vanderson Rocha ◽  
Irina Ionescu ◽  
Ricardo Pasquini ◽  
Richard Harris ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Cord Blood ◽  
Fanconi Anemia ◽  
Low Dose ◽  
Median Number ◽  
Cell Transplant ◽  
Alternative Source ◽  
Hematopoietic Stem ◽  
Cord Blood Transplant ◽  
Unrelated Cord Blood

Abstract Background: allogeneic hematopoietic stem cell transplant (HSC) is the only chance of cure in patients with Fanconi anemia (FA). Unrelated cord blood transplant is a possible alternative source of HSC. We report here a worldwide experience of unrelated cord blood transplant (UCBT) in a series of 72 patients with FA. Patients and transplant characteristics : This is a retrospective multicenter analysis of 72 patients (62 children, 12 adults) with FA complicated by severe aplastic anemia or leukemia/MDS. Median age was 8 years ( 1–45), median follow-up after UCBT 23 months. The unrelated CB was HLA identical for A, B DRB1 in 9 cases, had 1 HLA difference in 29 cases and 2 or 3 HLA differences in 33 cases. The median number of nucleated cells (NC) infused was 4.4x107/kg, of CD34+ 2.1x105/kg. Conditioning varied: 24 patients received low dose cyclophosphamide with low dose TBI/TLI, 33 Fludarabine with cyclophosphamide and TBI or Busulfan, 55 patients received ATG. GVH prophylaxis consisted of cyclosporine alone (16) or with prednisone (37). Results: CI of engraftment was 54%. In multivariate analysis: unfavourable factors were nb of HLA differences>2 (p .007) and NC infused <4.4x107/kg (p.04) CI of GVH> II was 32% and of cGVH 11%. Overall survival was 36%. In multivariate analysis, favourable factors were negative recipient CMV serology ( p.001), nb of NC infused> 4.4x107/kg (p.007) and use of Fludarabine (p.035). Causes of death were non engraftment :10 pts, GVH: 4 pts, infections: 15 pts and toxicity:15 pts. These results are quite similar to our current results of matched unrelated bone marrow transplant. Conclusion: results of unrelated cord blood transplants could be improved by better patient and cord blood selection with units closely HLA matched and high number of cells, Conditioning with Fludarabine seems to improve results. In FA, use of cord blood might be beneficial because of the reduction of the risk of GVH which might decrease the risk of long term cancers.

Efficacy and safety of micafungin in unrelated cord blood transplant recipients

2019 ◽  
Vol 98 (11) ◽  
pp. 2593-2600
Author(s):  
Takeo Yasu ◽  
Takaaki Konuma ◽  
Maki Oiwa-Monna ◽  
Mai Mizusawa ◽  
Masamichi Isobe ◽  
...  
Keyword(s):  
Cord Blood ◽  
Efficacy And Safety ◽  
Transplant Recipients ◽  
Cord Blood Transplant ◽  
Unrelated Cord Blood

The Effect of Obesity On Outcome of Unrelated Cord Blood Transplant in Children with Malignant Diseases.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2278-2278
Author(s):  
S. Pine Meghann ◽  
Li Wang ◽  
Frank Harrell ◽  
Richard Ho ◽  
Jennifer Domm ◽  
...  
Keyword(s):  
Cord Blood ◽  
Performance Status ◽  
Chronic Gvhd ◽  
Hla Antigens ◽  
Normal Weight ◽  
Obese Patients ◽  
Malignant Diseases ◽  
Cord Blood Transplant ◽  
Cord Blood Unit ◽  
Unrelated Cord Blood

Abstract Abstract 2278 Poster Board II-255 Obesity has become a pandemic in the US, affecting both children and adults. In the adult population, evidence suggests that obesity has an adverse impact on outcomes of hematopoietic stem cell transplant for various malignancies. We investigated the influence of obesity on children undergoing unrelated cord blood transplant utilizing data from the Cord Blood Transplant Study. To our knowledge, no data exists on the effect obesity has on key prognostic indicators for cord blood transplant for malignant diseases in children. There were 191 patients '18 years of age with malignant diseases prospectively enrolled on a National Heart Lung Blood Institute (NHLBI) sponsored cord blood transplant study between 1999 and 2003. Data set was obtained after signed agreement with the NHLBI and local IRB approval. All patients received myeloablative preparative regimens with either total body irradiation and cyclophosphamide (N=172) or busulfan and melphalan (N=19). In addition, all patients received anti-thymocyte globulin as part of their conditioning regimens. Graft versus host disease (GVHD) prophylaxis included cyclosporine and prednisone. Children were classified into groups according to body mass index (BMI) percentile. Normal weight was defined as BMI between the 5th and 85th percentile, overweight between the 85th and 95th percentile, obesity above 95th percentile for age and gender according to the Center for Disease Control and Prevention (CDC) guidelines. For the overall survival (OS) and disease free survival (DFS), the Cox regression model was used to test the effect of BMI while controlling for age, gender, performance status (<90 versus ≥90), HLA match (≤4/6 versus ≥5/6 HLA match), total nucleated cell count (TNC) per kg infused and CMV status. For neutrophil and platelet engraftment, transplant related mortality (TRM), grade II-IV acute GVHD, and chronic GVHD, competing risks regression analyses were used to test effect of BMI while controlling for other covariates. The median age was 7.59 years (range 2.07 – 17.90) with 113 (59%) male. 160 patients (84%) had a performance status of ≥90. 51 patients (27%) had acute myelogenous leukemia (AML), 109 patients (57%) had acute lymphoblastic leukemia (ALL) and 30 patients (16%) had other malignant diseases. 119 patients (62%) received a cord blood unit matched at 3/6 or 4/6 HLA antigens and 72 patients (38%) received a cord blood unit matched at 5/6 or 6/6 HLA antigens. The median TNC per kg infused was 5.2 × 107/kg (range 0.15-80.9 × 107/kg). Of the 191 total patients who were classified by their BMI percentiles, 117 patients (61%) were normal weight, 35 patients (18%) were overweight and 39 patients (20%) were obese. The two groups were not significantly different in sex distribution (p=0.25), diagnosis (p=0.13), performance status (p=0.91), median TNC received (p=0.49) or CMV status (p=0.47). Obese patients were significantly younger with a median age of 5.7 years compared to 8.9 years in normal weight children (p=0.002). Time to neutrophil and platelet engraftment, TRM, risk of grade II-IV acute GVHD, DFS and OS were not significantly different in overweight or obese patients compared to normal weight patients. There was a trend towards increased risk of chronic GVHD in obese patients (p=0.045) compared to normal weight patients. In conclusion, obesity has no significant effect on multiple outcomes after unrelated cord blood transplant in children with malignant diseases. Disclosures: No relevant conflicts of interest to declare.

Unrelated cord blood transplant for refractory langerhan cell histocytosis

2000 ◽  
Vol 22 (4) ◽  
pp. 385
Author(s):  
R. Nagarajan ◽  
J. P. Neglia ◽  
N. K.C. Ramsay ◽  
K. S. Baker
Keyword(s):  
Cord Blood ◽  
Cord Blood Transplant ◽  
Unrelated Cord Blood
Sign in / Sign up

Export Citation Format

Share Document